Latest Cytomegalovirus Stories
DURHAM, N.C., July 20, 2011 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer, will participate on a panel at Infocast's 9th Annual Biodefense Vaccines & Therapeutics Conference on July 22nd, 2011, 10:30 am ET.
Durham, N.C., July 13, 2011 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced that patient dosing has begun in the AdV HALT Trial (A Randomized, Placebo-Controlled, Multi-site Phase 2 Study Evaluating the Safety and Efficacy of Preemptive Treatment with CMX001 for the Prevention of Adenovirus Disease Following Hematopoietic Stem Cell Transplantation [HSCT]).The company also announced that the U.S.
DURHAM, N.C., June 27, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced an agreement with the Biomedical Advanced Research and Development Authority (BARDA) of the United States Department of Health and Human Services (HHS) that will resolve the Government Accountability Office (GAO) review of the recent sole source contract awarded to SIGA Technologies, Inc.
Swabbing a newborn's mouth for saliva can be used to quickly and effectively screen for cytomegalovirus (CMV) infection, a leading cause of hearing loss in children.
Although cytomegalovirus infection is a known cause of birth defects, including permanent hearing loss, most CMV infections in infants are not identified early, when interventions can lessen the effects of hearing loss.
New simple saliva test can identify cytomegalovirus (CMV) infection, known to cause birth defects, such as permanent hearing loss.
At present, while there is no cause known for this condition, patients with MS seem to have genetic vulnerability to certain environmental factors that could trigger this condition, such as the Epstein-Barr virus.
Research conducted at Oregon Health & Science University's Vaccine and Gene Therapy Institute (VGTI) has developed a vaccine candidate in non-human primates that may eventually lead to a vaccine against Human Immunodeficiency Virus (HIV).
DURHAM, N.C., May 11, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing oral antiviral therapeutics, today presented data showing that the majority of immunocompromised patients with severe adenovirus infections who were treated with Chimerix's lead antiviral compound, CMX001, had a > 99% decrease in viral load compared to baseline after two weeks of therapy.
Cytomegalovirus, a herpes viral genus, is known in humans as HCMV. It is part of the Betaherpesvirinae subfamily. Other herpesviruses fall into the subfamilies of Alphaherpesvirinae or Gammaherpesvirinae. xHCMV infections are frequently associated with salivary glands. It can be lethal for people who are immunocompromised. Other CMV viruses are found in several mammal species, but species isolated from animals differ from HCMV in terms of genomic structure. HCMV is found all over the...
- The governor of a province or people.